Retatrutide – 5mg/10mg/15mg

Primary Uses of Retatrutide for Sale

Weight Loss (Obesity Management)

If you’re sourcing retatrutide for sale for weight loss research, recent studies provide groundbreaking insights. A Phase 2 trial published in The New England Journal of Medicine (June 2023) reported that adults with obesity (without diabetes) lost up to 24.2% of body weight (about 58 lbs) over 48 weeks at the highest 12 mg dose. This outcome rivals results from bariatric surgery.

Retatrutide works through:

• Appetite suppression via GLP-1 and GIP

• Increased energy expenditure via glucagon

• Slowed gastric emptying, which enhances fullness

These mechanisms combined make retatrutide for sale a top candidate for obesity research protocols.

Type 2 Diabetes

In a separate trial published in The Lancet (August 2023), researchers observed that individuals with type 2 diabetes experienced dose-dependent weight loss (up to 16.94% at 12 mg) and significant HbA1c improvements over 36 weeks. The triple agonist action of retatrutide—activating GLP-1, GIP, and glucagon receptors—helps enhance insulin secretion and stabilize glucose levels.

This positions retatrutide for sale as a promising tool for type 2 diabetes studies.

Fatty Liver Disease (MASLD)

Retatrutide also demonstrated effectiveness in reducing liver fat in a substudy from the obesity trial. At the 12 mg dose, liver fat dropped by up to 82.4%, and 9 out of 10 participants achieved normalized levels (<5%) after 48 weeks.

These results indicate strong potential for retatrutide for sale in research related to MASLD (formerly NAFLD) and metabolic liver dysfunction.

Cardiometabolic Benefits

Exploratory trial endpoints showed additional benefits such as improved:

• Blood pressure

• Triglycerides

• LDL cholesterol

• Fasting glucose

This suggests that retatrutide for sale could play a role in broader cardiometabolic disease studies.

How Retatrutide for Sale Is Used in Research

Administration

Retatrutide is delivered via once-weekly subcutaneous injection, which is consistent with other GLP-1-based agents.

Dosage

Tested doses range from 1 mg to 12 mg, with higher doses delivering stronger outcomes. Researchers typically begin with lower doses (e.g., 2 mg or 4 mg) and gradually escalate to minimize side effects. 👉 To learn more about peptides and their research use, read our full peptide introduction guide.